ArticleJournal of clinical hypertension (Greenwich, Conn.)2026
Risk Factors and Adverse Perinatal Outcomes in Severe Preeclampsia Complicated by HELLP Syndrome.
Article in Journal of clinical hypertension (Greenwich, Conn.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
This study investigated the risk factors and adverse perinatal outcomes of severe preeclampsia complicated with HELLP (Hemolysis, Elevated Liver Enzymes, and Low Platelet Count syndrome). A total of 170 patients with severe preeclampsia and 30 healthy pregnant women admitted to Wuxi Maternal and Child Health Hospital from January 2020 to October 2023 were enrolled. Of the 170 patients, 30 were complicated by HELLP syndrome and 140 were not; 30 healthy women served as controls. Clinical data, laboratory results, and pregnancy outcomes were compared. Risk factors were analyzed by logistic regression, and predictive efficacy was evaluated by ROC curves. Maternal and neonatal outcomes were assessed, and correlations with risk factors were analyzed. Patients with severe preeclampsia had higher age, BMI, and blood pressure but lower gestational weeks than controls (p < 0.05). In the HELLP group, D-dimer, bilirubin, liver enzymes, and lactate dehydrogenase (LDH) were significantly elevated, while platelets, albumin, and globulin were reduced compared with the non-HELLP group (p < 0.05). Multivariate analysis identified D-dimer and LDH as independent risk factors. ROC analysis showed AUCs of 0.929 for D-dimer, 0.937 for LDH, and 0.956 for their combination, with cutoffs of 3.26 mg/L and 261.60 U/L, yielding 94.4% sensitivity and 92.6% specificity. Adverse outcomes, including stillbirth, preterm labor, neonatal asphyxia, and MICU transfer, were more frequent in HELLP patients (p < 0.05). Elevated D-dimer and LDH correlated with fetal growth restriction and neonatal asphyxia. In conclusion, D-dimer and LDH are independent predictors of HELLP syndrome and adverse perinatal outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.